Fishers biotech firm lands additional FDA approval for imaging product
Dr. Clint Bahler, an Indiana University Health urologist, reviews scans of cancer patients that are more readable thanks to an imaging agent called...
Dr. Clint Bahler, an Indiana University Health urologist, reviews scans of cancer patients that are more readable thanks to an imaging agent called Illuccix. (Photo courtesy of Telix) An Australian biotech company that has its U.S. headquarters in Fishers has received additional approval from the U.S. Food and Drug Administration. Telix Pharmaceuticals said Thursday that its lead prostate cancer imaging product, Illuccix, is now authorized for select patients who may be eligible for another FDA-approved therapy developed in Indiana.